Oxfenicine is a CPT-1b-specific inhibitor. It must be transaminated to its active form, 4-hydroxyphenyl-glyoxylate, which is competitive with carnitine, preventing the formation of acylcarnitine. Because CPT-1b shows the highest sensitivity to 4-hydroxyphenyl-glyoxylate, inhibition of fatty acid oxidation by oxfenicine takes place selectively in those tissues that express this CPT isoform. It may be effective for treating noninsulin-dependent diabetes mellitus which is characterized by elevated fatty acid levels and obesity. In 1980 it was also tested in preclinical models of angina pectoris and ischemia.

Meteneprost (9-deoxo-16, 16-dimethyl-9-methylene PGE2) is a prostaglandin E2 analog. It exerts uterine-stimulating potency: meteneprost is able to both stimulate uterine contractions and dilate the cervical canal. It was studied as an abortifacient in early pregnancy.

Estrazinol is a synthetic estrogen.

Oximonam (also known as SQ 82,291) was developed as a monobactam antibiotic that had shown good activity against different bacteria of the family Enterobacteriaceae and Haemophilus influenzae and was no activity at all against staphylococci and against Pseudomonas aeruginosa.

Cicloprofen is fluorene derivative patented by American pharmaceutical company E. R. Squibb as anti-inflammatory agents. Cicloprofen is potent cyclooxygenase inhibitor. Cicloprofen undergoes hydroxylation of the fluorene rings and conjugation with glucuronic acid or sulfate and metabolic transformation leading to stereospecific inversion of the ( - )-enantiomer of Cicloprofen to its (+)-antipode

Meclorisone is a synthetic corticosteroid exerting anti-inflammatory activity.

Trimoprostil is a synthetic prostaglandin E2 derivative and prostanoid receptor agonist, with potential gastric secretion inhibitor and antiulcerogenic activity. It has been shown to reduce hydrogen ion secretion, to enhance gastric bicarbonate secretion and to reduce aspirin-induced gastric mucosal injury. In contrast to many E prostaglandins, it does not lower the tone of the lower oesophageal sphincter. Trimoprostil was well tolerated and more effective than placebo in the treatment of mild to moderate symptomatic reflux oesophagitis. It may be protective to human squamous oesophageal mucosa. Trimoprostil was not as effective as cimetidine in the treatment of duodenal ulcer.

Clioxanide is a derivative of diiodobenzanilide, developed by Parke, Davis & Co in the 1960s. It was used as an antihelmintic against Fasciola hepatica and Haemonchus contortus. In sheep, the compound was demonstrated high efficiency (greater than 90%) when administered at 20-40 mg/kg. Later it was found that clioxanide is an inhibitor of Type III Secretion in Yersinia bacteria.

Triamcinolone acetonide- 21-dihydrogen phosphate is the long-acting derivative of a synthetic glucocorticoid triamcinolone. Triamcinolone acetonide has eight times more potency than prednisolone. Triamcinolone acetonide- 21-dihydrogen phosphate used for intravenous injection. It is supposed to be hydrolyzed rapidly in the body to form the free corticoid alcohol.

Colforsin (NKH477) is a water-soluble forskolin derivative. NKH477, like forskolin, showed adenylate cyclase stimulant activity in guinea pig ventricular membrane but did not inhibit Na+, K(+)-ATPase or phosphodiesterase (PDE) activity. The compound was developed by a Japanese company Nippon Kayaku. Colforsin daropate, a prodrug of colforsin, is marketed in Japan for the treatment of acute heart failure under tradename Adehl.